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This study explored attitudes toward hypothetical genetic testing for posttraumatic
stress disorder (PTSD) and addiction among veterans. We surveyed a random sample
of community-based veterans (n = 700) by telephone. One year later, we asked the
veterans to provide a DNA sample for analysis and 41.9% of them returned the DNA
samples. Overall, most veterans were not interested in genetic testing neither for PTSD
(61.7%) nor for addiction (68.7%). However, bivariate analyses suggested there was
an association between having the condition of interest and the likelihood of genetic
testing on a 5-point scale (p < 0.001 for PTSD; p = 0.001 for alcohol dependence).
While ordinal regressions confirmed these associations, the models with the best statistical fit were bivariate models of whether the veteran would likely test or not. Using
logistic regressions, significant predictors for PTSD testing were receiving recent mental
health treatment, history of a concussion, younger age, having PTSD, having alcohol
dependence, currently taking opioids for pain, and returning the DNA sample during
the follow-up. For addiction testing, significant predictors were history of concussion,
younger age, psychotropic medication use, having alcohol dependence, and currently
taking opioids for pain. Altogether, 25.9% of veterans reported that they would have
liked to have known their genetic results before deployment, 15.6% reported after
deployment, and 58.6% reported they did not want to know neither before nor after
deployment. As advancements in genetic testing continue to evolve, our study suggests
that consumer attitudes toward genetic testing for mental disorders are complex and
better understanding of these attitudes and beliefs will be crucial to successfully promote
utilization.
Keywords: genetic testing, posttraumatic stress disorder, addiction, veterans, psychiatric genetics

INTRODUCTION
Understanding of the genetic bases of psychiatric disorders continues to improve, despite the
complexity and various gene–environment interactions that can influence such behaviors (1). The
potential benefits of genetic testing may include better diagnostic screening, early prevention and, in
the case of Mendelian genetic disorders, the ability to make more informed reproductive decisions
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MATERIALS AND METHODS

(2, 3). Conversely, genetic testing could impact well-being (4, 5),
raise the potential for discrimination (2, 3), and cause conflict
within families (4). Questions surrounding privacy, as well as
who should be tested and why, also present multifaceted dilemmas (2, 4). Genetic testing for psychiatric disorder risk is likely
to become increasingly incorporated into clinical practice in the
future, especially as more direct-to-consumer testing products
become available (6).
A review of studies on general consumer attitudes surrounding genetic testing for psychiatric disorders identified several
areas for future study: specifically, the need to study individuals
without psychiatric disorders or not involved in genetics-related
research, and the need for larger samples (2). Only one study to
date has evaluated veterans’ attitudes toward psychiatric disorder
genetic testing (7). This study found that veterans with posttraumatic stress disorder (PTSD) viewed genetic testing for PTSD less
favorably than those without PTSD and were more likely to fear
insurance discrimination.
Attitudes toward genetic testing for psychiatric disorders
among military veterans are largely unknown despite the high
prevalence of certain psychiatric disorders among veterans and
the regular screening of patients at VA facilities for psychiatric
disorders, including PTSD and addiction (8, 9). Prevalence
estimates of PTSD range from 10% in male Gulf War veterans
to 15% in Vietnam-era male veterans, compared to 3.6% of
males in the general population (10–13). Additionally, 2 out
of every 10 veterans with PTSD also live with substance use
disorders (13).
Consumer attitudes toward genetic testing for psychiatric
disorders are mixed (3, 5, 7). In one study, 83% of family members of individuals with schizophrenia reported interest in
genetic testing for this condition (14). Additionally, individuals with a family history of bipolar disorder generally endorsed
that they would pursue genetic testing if the assessment has
high diagnostic certainty, but fewer wanted their children
tested at birth (3). Unaffected relatives of individuals with
psychiatric disorders emphasized the importance of genetic
counseling prior to testing to provide consumers with an accurate assessment of potential risk in the context of reproductive
decision-making (15). Consumers with psychiatric disorders
not only reported interest in contributing to genetic research
but also reported concerns regarding having to make “difficult
choices,” the perception of certain lives as more valuable than
others, and the possibility of discrimination (5). Individuals
with alcohol use disorders were willing to provide genetic
samples but also expressed concerns surrounding health
insurance denial, employment discrimination, and identity
theft (16).
In this study, we randomly surveyed a cohort of 700 community-based U.S. military veterans with and without psychiatric
disorders regarding their attitudes about hypothetical genetic
testing at baseline for PTSD and addiction. All study veterans
served at least one warzone deployment and were considered to
be at risk for these conditions post deployment (17). One year
later, we recontacted these veterans and asked them to return a
DNA sample for genetic analyses.
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Participants

The study cohort included a random sample of community-based
U.S. military veterans (n = 700) recruited as part of a broader
study of the health effects of military service (18). For our sample,
we created a computer-generated random number, which was
then assigned to each veteran identified in our Health System.
Based on this number, patients were randomly selected for survey
interviews. All participants were outpatients in the multihospital
system and self-identified as veterans, which was verified during
the survey recruitment. Veterans with and without psychiatric
disorders were interviewed.
Inclusion criteria were English-speaking, had one or more
deployments in a warzone, and had an age less than 75 years.
Institutionalization and an inability to complete a 45-min interview were exclusion criteria. The study participation rate was
estimated to be 65% (19). The Health System’s Institutional Review
Board approved the study protocol, and all participants provided
verbal informed consent for the baseline phone survey and written
consent for the DNA sample at follow-up. A small incentive was
provided to complete the survey ($15) and to return the DNA
sample by mail ($15).

Telephone Interviews

The interviews were administered by telephone by trained mental
health interviewers working in a supervised, professional survey
research center from December 2011 through January 2012. The
survey instruments utilized were used in previous studies (20–25)
and validated in national and regional trauma studies involving
over 30,000 respondents exposed to psychological trauma (24,
26). Comparison of telephone vs. in-person surveys using survey
instruments suggests similar results in mental health studies
(27, 28).
Participants provided information on military service branch,
deployment history, smoking history, mental health history, concussion history, and other demographic and medical information
(18). They were also screened for probable alcohol dependence
using the CAGE (Cut Down, Annoyed, Guilty, and Eye Opener)
questionnaire (29). Combat exposure was assessed using a version of the Combat Experience Scale (30).
Participants answered questions regarding their attitudes
toward hypothetical genetic testing at baseline for PTSD and
addiction after the following introduction was provided: “Genetic
tests are being developed for different medical problems. Soon
genetic tests may be available to predict a person’s risks for addiction and posttraumatic stress disorder. If such genetic tests were
available, how likely would you be to have this genetic test?” This
question was assessed on a 5-point Likert Scale, ranging from
“extremely likely” to “not likely at all.” Following this question,
they were asked two open-ended questions about their answers
to these Likert-scaled questions (i.e., “Why did you respond
like you did for addiction?”). Participants were also asked when
they would have liked to have known their genetic risks (i.e.,
before deployment, after or neither before or after deployment).
Measures of trust, discrimination, and concerns about privacy
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were not explicitly assessed in the current survey. However, we
did use open-ended survey questions as a way to capture the
concerns of veterans, as is commonly done in behavioral research
(31, 32). We inquired about health insurance status, employment
status, and use of VA services to add to our analyses to assess the
impact of these variables on testing responses.
Our open-ended questions were administered and coded
in accordance with standard procedures for survey research
(31, 32). Open-ended questions were recorded verbatim during
the interview. Each question was probed up to three times for
specificity, if necessary. For instance, if a vague response was
given (e.g., “it depends …”), the interviewer probed the respondent to be more specific. After survey completion, the verbatim
responses were manually coded. Following this, tabulations were
compiled and coding was revised in consultation the with study
Principal Investigator to capture any new categories that emerged
or to collapse existing categories (31, 32).

Table 1 | Sample characteristics (N = 700).
Study variables

DNA Sample Collection

Approximately 1 year after the survey, veterans were recontacted
and asked to provide a DNA sample using Orogene DNA kits
manufactured by Genotek, Inc. (Ottawa, ON, Canada). Those
who agreed to test where mailed a saliva kit with instructions
to complete and return to the study team using a postage-paid
return envelope. Altogether, 41.9% (95% CI = 38.2–45.6) of
veterans returned their DNA kits to the study team.

Statistical Analyses

Descriptive statistics characterized the study sample. Likelihood
of testing was analyzed both as an ordinal scale and collapsed
into binary outcome variables (extremely likely, very likely, and
likely = yes; not very likely, not likely at all = no) for PTSD and
addiction, respectively, based on our statistical results. Since the
dichotomous measures demonstrated the best statistical fit (33, 34),
we present these results in the current paper. Next, multivariable
logistic regressions (33), using stepwise backwards elimination
were used with the p-value ≥0.05 for variable elimination in order
to identify the best predictor variables associated with the likelihood of proving a DNA sample for testing. Our candidate predictor variables included multiple tours, poor/fair current health,
high combat exposure, age, education, race, sex, being employed,
having health insurance, having current PTSD, having current
depression, using the VA for health care, having a positive current
screen for alcohol dependence, using mental health services in
past year, a history of concussion, using psychotropic medications
in past year, using painkillers in past year, and returning the DNA
sample at follow-up. Verbatim responses were manually coded
by study staff and grouped categorically. “Don’t know” responses
for the testing questions (<1%) were deleted for the purposes of
regression analyses. Statistical analyses were conducted using
Stata, version 13.1 (Stata Corp, College Station, TX, USA, 2014).

n (%)

Age
18–39
40–64
65+
Male
White race
Married
Employed full-time or part-time
Have health-care insurance
Some college or higher
Multiple warzone deployments
Currently use VA for health care
Received mental health treatment, past year
Reports poor/fair current health
Returned DNA sample

66 (9.4)
415 (59.3)
219 (31.3)
671 (95.9)
653 (93.3)
557 (79.6)
313 (44.7)
674 (96.3)
399 (57.0)
200 (28.6)
283 (40.4)
153 (21.9)
221 (31.6)
293 (41.9)

Warzone service
Vietnam
Gulf war
Iraq/Afghanistan
Other

504 (72.0)
68 (9.7)
96 (13.7)
32 (4.6)

Substance use/medication use/combat
Smoked 100+ cigarettes in lifetime
Drank nearly every day in past year
Heavy drinking in the past 30 days
Alcohol dependence in past yeara
Used psychotropic medications in past year
Used prescription painkillers in past year
Combat was major traumatic event
High combat exposure history
History of concussion during deployment

505 (72.1)
66 (9.4)
83 (11.9)
87 (12.4)
144 (20.6)
97 (13.9)
569 (82.3)
148 (21.1)
181 (25.9)

Psychiatric disorders
Lifetime posttraumatic stress disorder (PTSD)
PTSD in past year
Subclinical PTSD in the past yearb
Lifetime major depression disorder
Major depression in past year

67 (9.6)
47 (6.7)
109 (15.6)
129 (18.4)
44 (6.2)

CAGE questionnaire (29).
Breslau criteria for PTSD (35).

a

b

or higher education (57%), had health insurance (96.3%), were
Vietnam veterans (72%), and a significant number (40.4%) currently used the VA health-care system (Table 1). The majority had
a history of cigarette smoking (72.1%), and approximately 12%
had a recent history of alcohol misuse (heavy drinking, 11.9%;
positive alcohol dependence results on the CAGE scale, 12.4%).

Mental Health History

RESULTS

A significant number of veterans were classified as having high
combat exposure (21.1%), lifetime PTSD (9.6%), lifetime major
depression (18.4%), poor or fair current health (31.6%), and
having used prescription opioids in the past 12 months (13.9%).
Approximately 20% of veterans were taking psychotropic medications (20.6%), had a recent mental health-related visit (21.9%),
or had a history of concussion during their deployment (25.9%).
In addition, more than 80% of veterans (82.3%) reported that
being in combat was a major traumatic event for them (Table 1).

Sample

Attitudes about Genetic Testing

The majority of participants responded that they were “Not
Likely at All,” or “Not Very Likely” to pursue genetic testing for

Most veterans were between 40 and 64 years old (59.3%), male sex
(95.9%), white race (93.3%), married (79.6%), had some college
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Table 2 | Veterans’ interest in genetic testing for posttraumatic stress
disorder (PTSD) and addiction (N = 700).

Table 3 | Stepwise logistic regressions predicting genetic testing
(N = 700).a

Testing interest/attitudes

n (%)

Yes/no, n (%)a

Predictor variables

Genetic testing for PTSD
Extremely likely
Very likely
Likely

75 (10.7)
77 (11.0)
118 (16.9)

Yes, 270 (38.6)

Not very likely
Not likely at all

93 (13.3)
334 (47.4)

No, 427 (61.7)

Don’t know/uncertain
Genetic testing for addiction
Extremely likely
Very likely
Likely
Not very likely
Not likely at all
Don’t know/uncertain

Yes, 213 (30.4)

87 (12.4)
394 (56.3)

No, 481 (68.7)

Yes, interest in genetic testing for addictionb,e
Age (years)
0.98 (0.97–0.99)
Current alcohol dependencec
1.85 (1.15–2.98)
Used psychotropic medications in past year
1.57 (1.04–2.35)
Used prescription painkillers in past year
1.73 (1.09–2.76)
History of concussion during deployment
1.71 (1.18–2.48)

6 (0.9)

0.005
0.011
0.030
0.021
0.004

a
Variables assessed in backward stepwise logistic regression included serving multiple
tours, having poor/fair health, high combat exposure, age, having some college or
more, white race, male sex, employed full-time/part-time, having health insurance,
current PTSD, current depression, currently using VA, having a positive screen for
alcohol dependence, used mental health services in past year, having history of
concussion, used psychotropic medications in past year, used painkillers in past year,
and return of the DNA sample at follow-up. Variables with p ≥ 0.05 were removed from
the analysis.
b
Yes = extremely likely, very likely, likely. No = not very likely, not likely at all.
c
CAGE questionnaire (29).
d
Area under ROC = 0.71; Hosmer–Lemeshow χ2 = 5.72, df = 8, p = 0.68; Pseudo
R2 = 0.12.
e
Area under ROC = 0.65; Hosmer–Lemeshow χ2 = 8.79, df = 8, p = 0.36; Pseudo
R2 = 0.05.

Would liked to have known genetic results
Before deployment
181 (25.9)
After deployment
109 (15.6)
Neither before or after deployment
410 (58.6)
Yes = extremely likely, very likely, and likely. No = not very likely, not likely at all.

a

PTSD (61.7%, Table 2) or for addiction (68.7%). Additionally,
25.9% would have wanted to know about their genetic risk before
deployment, 15.6% after deployment and 58.6% did not want
to know their genetic risk before or after deployment (Table 2).
While bivariate associations were found for current PTSD and
addiction and the likelihood of testing based on Spearman corrections (p < 0.001 for PTSD; p = 0.001 for addiction), the ordinal
logistic regression results for these analyses fit poorly (Pseudo
R2 = 2% for addiction; Pseudo R2 = 6% for PTSD). Consequently,
we collapsed these results into binary “yes/no” measures and used
logistic regressions for these analyses.
In veterans who did endorse interest in genetic testing for
PTSD or addiction, the final stepwise logistic regression models
found seven significant predictors for the likelihood of PTSD testing and five predictors for addiction testing (Table 3). For PTSD
testing, receiving recent mental health treatment (OR = 2.30,
CI = 1.51–3.52,p < 0.001), history of concussion (OR = 2.01,
CI = 1.37–2.93, p < 0.001), younger age (OR = 0.97, OR =
0.96–0.99, p < 0.001), current PTSD (OR = 4.07, CI = 1.80–9.20,
p = 0.001), current alcohol dependence (OR = 2.12, CI = 1.29–3.50,
p = 0.003), use of opioids for pain (OR = 1.69, CI = 1.04–2.74,
p = 0.033), and returning the DNA sample at follow-up (OR = 1.41,
CI = 1.01–1.99, p = 0.047) were associated with the likelihood of
genetic testing for PTSD at baseline. For addiction testing, history
of concussion (OR = 1.71, CI = 1.18–2.48, p = 0.004), younger
age (OR = 0.98, CI = 0.97–0.99, p = 0.005), currently taking psychotropic medications (OR = 1.57, CI = 1.04–2.35, p = 0.030),
current alcohol dependence (OR = 1.85, CI = 1.15–2.98,
p = 0.011), and the use of prescription opioid painkillers in the
past year (OR = 1.73, CI = 1.09–2.76, p = 0.021) were associated
with the likelihood of genetic testing for addiction.
The results for the open-ended reasons given for both
interest in and no interest in genetic testing for PTSD and
addiction, respectively, are shown in Table 4. Reasons given
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p-Value

Yes, interest in genetic testing for posttraumatic stress disorder (PTSD)b,d
Age (years)
0.97 (0.96–0.99)
<0.001
Current alcohol dependencec
2.12 (1.29–3.50)
0.003
Current PTSD
4.07 (1.80–9.20)
0.001
Mental health treatment past year
2.30 (1.51–3.52)
<0.001
History of concussion during deployment
2.01 (1.37–2.93)
<0.001
Used prescription painkillers in past year
1.69 (1.04–2.74)
0.033
Returned DNA sample
1.41 (1.01–1.99)
0.047

3 (0.4)
60 (8.6)
54 (7.7)
99 (14.1)

OR (95% CI)

Table 4 | Open-ended reasons given for interest/no interest in genetic
testing for posttraumatic stress disorder (PTSD)/addiction.
Reasons given for PTSD testing (n = 267)
• Curious/would like to know (25%)
• Self-benefit/knowledge (22%)
• Already diagnosed (15%)
• To help others (11%)
Reasons given for no PTSD testing (n = 417)
• Does not have PTSD (31%)
• Unnecessary (19%)
• Older age (18%)
Reasons given for addiction testing (n = 210)
• Self-benefit/knowledge (29%)
• Curious/would like to know (24%)
• Family history (13%)
Reasons given for no addiction testing (n = 470)
• No addiction history (42%)
• Unnecessary (14%)
• Older age (13%)

for interest in genetic testing for both PTSD and addiction
were mostly related to self-benefit and gaining additional
knowledge (for PTSD, 25 + 22 = 47%; for addiction,
29 + 24 = 53%). Reasons given for not testing are related to
not having the condition or being reported as unnecessary
(for PTSD, 31 + 19 = 50%; for addiction 42 + 14 = 56%). Concerns
about privacy, confidentiality, discrimination, insurance coverage, etc., were not mentioned by the veterans.
4
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DISCUSSION

prior to testing can help to mediate misconceptions and fears
surrounding uncertainty (40), perceived risk (41, 42), and stigma
(43) and improve knowledge about causes of psychiatric disorders
(41, 43). However, for conditions such as PTSD and addiction,
which are complex and multifactorial disorders, genetic counseling is limited at this time because the genetic variants known
to date only explain a small percentage of the phenotypic variance
(37, 44). Nevertheless, the epidemiology, biology, diagnosis, associated comorbidity, and PTSD treatment options are considered
well understood at this time (24, 26, 45, 46).
To date, our study is the largest investigation of attitudes
toward psychiatric genetic testing and included individuals with
and without psychiatric disorders who were not already engaged
in genetic testing. The prevalence of psychiatric disorders in our
community-based veteran sample resembled the general U.S.
population more than many VA-based cohorts (18), potentially
expanding the applicability of our findings. One limitation of
this study was that our cohort was largely homogenous (>90%
male, White, and older) Vietnam-era veterans (72%), which
may not represent younger or female veterans’ views toward
genetic testing for PTSD and addiction. Future studies should
include more diversity and evaluate a wider range of psychiatric
disorders.
In summary, the majority of veterans did not express interest
in genetic testing for PTSD or addiction, two psychiatric disorders of particular relevance to this population and that are of high
interest in the VA system and to the veteran community (18, 46).
As prospective discoveries and subsequent advancements
continue to improve genetic testing, a more comprehensive
understanding of views regarding screening will become
increasingly imperative to expand its clinical application. It is
important to emphasize that PTSD, in particular, is not just
another mental disorder for veterans but also a compensated
medical condition associated with military service and warfighting worldwide.

The principal study finding was that the majority of veterans were
not interested in hypothetical genetic risk testing for PTSD (62%)
or addiction (69%) at baseline. Most veterans (58.6%) reported
that they would not want to know their genetic status either before
or after deployment. The most frequent reasons for lack of interest were not feeling at risk for these disorders and questioning
the utility of genetic testing. Participants did not mention trust,
ethical issues, or concern about employment. However, the
majority of the veterans surveyed (55.3%) were not employed and
were over 40 years old (90.6%). In addition, 96.3% reported currently having insurance coverage. Previously, challenges trusting
researchers, privacy, discrimination concerns, and questions as
to how genetic information would assist in psychiatric treatment
were cited as reasons for testing hesitancy (5, 7).
Having current PTSD increased the likelihood of interest in
genetic testing for PTSD fourfold (OR = 4.07). Recent mental
health treatment, younger age, a history of concussion, a positive
screen for alcohol dependence, a use of opioid pain medicines,
and having returned the DNA sample at the follow-up, also
was associated with interest in genetic testing for PTSD. Our
findings differ from a previous study that found veterans in the
VA system with PTSD expressed less favorable attitudes toward
genetic testing than those without PTSD (7). Our larger sample
size, older cohort, and our non-VA-based sample may account
for the differences in results. For addiction, history of concussion during deployment, younger age, taking psychotropic
medications, a positive alcohol dependence screen, and recent
use of opioids for pain were associated with increased interest
in testing.
Genetic testing for psychiatric disorder risk would be most
useful if testing occurred before the onset of symptoms, or
specifically in veterans, before combat exposure. Testing has the
potential to promote the practice of precision medicine (36) by
informing prevention approaches at the individual level. Early
testing could identify and target individuals at high risk via programs that include psychoeducation and heightened surveillance
(37). However, participants in our study expressed little interest
in genetic testing for two psychiatric disorders, citing often that
they did not have that problem or condition. Future studies could
evaluate whether interest in genetic testing for PTSD or addiction
increases when tests are available to the patient or occurs at a
younger age. When participants did endorse interest in genetic
testing, reasons cited were most commonly for self-benefit and
gains in knowledge. Highlighting these potential benefits of testing could improve interest and participation. Also noteworthy
is that the current study was a hypothetical assessment, since no
genetic testing was actually available at the time of the baseline
survey.
Genetic counseling, including education surrounding the
clinical utility of genetic testing and the protections afforded by the
Genetic Information Non-discrimination Act (38), may increase
interest in testing; however, privacy and discrimination were not
issues for veterans in the current study. Moreover, counseling
may move patients closer toward acceptance of these disorders,
leading to greater treatment-seeking behaviors (39). Counseling
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